REMARKS

Claims 2 to 7 are pending. Claim 1 has been cancelled. No claims are allowed.

Claims 2 and 3 have been amended as in the parent application. The claims are thus believed to be allowable.

The term "exposing" is consistent with the language in the claims of the parent application. The amount is an "antihelminthic amount". This is the language used in the allowed claims in the parent application.

Independent Claims 2 and 3 have been amended to specify that "each R" contains 1 to 12 carbon atoms. The objectionable term "substituted" has been deleted. Thus it is believed that the rejections under 35 USC 112, first paragraph, have been overcome. Reconsideration is requested.

Claims 1, 2, 6 and 7 were rejected under 35 USC 102(b) as anticipated by Spainhour et al (1997). Claims 1 to 7 were also rejected under 35 USC 103(a) over this reference.

Claims 2 to 7 have been amended to not include emodin. In order to clearly distinguish the compounds used in Applicants' method, R has been defined to not include a hydroxyl group in the 3 or R position as in emodin. Thus the claims are novel over this reference.

One skilled in the art could not predict from the art that the claimed compounds could be used to inhibit *Schistosoma* sp. since the claimed compounds with the claimed R groups are very different from anthraquinones with hydroxyl groups in the **3** or R position. The plants from which the anthraquinones of the claims were isolated are very different. The synthesis procedures to modify emodin to the compounds used in the method are not disclosed in the art. Reconsideration of this rejection is requested.

It is now believed that Claims 2 to 7 are in condition for allowance. Notice of Allowance is requested.

Respectfully,



Ian C. McLeod
Registration No. 20,931

McLeod & Moyne, P.C.
2190 Commons Parkway
Okemos, Michigan 48864
(517) 347-4100
Fax: (517) 347-4103